MetaCap

Neurogene Inc. (NGNE)

NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

22.15-0.78 (-3.40%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NGNE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$458.53M
EPS (TTM)
-$5.03
52-week range
15.93 – 43.66
Day range
22.03 – 22.90
Volume / Avg
178.26K / 307.78K
Beta
—

52-week range

$15.93$43.66

NGNE stock today

On Nov 20, NGNE ended the session at $22.15, shedding $0.78 (3.40%), versus the S&P 500's 3.70% decline. At this level, NGNE sits in the middle of its 52-week range of $15.93 to $43.66: 49.3% below the high, set on Jul 9, 2026 and 39.0% above the low. NGNE is up 7.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.4%.

Neurogene has posted a net loss over the last twelve months (EPS of -$5.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Neurogene

Company profile

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Rachel L. McMinn Ph.D.
Headquarters
New York, NY
Employees
131
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Neurogene generated $0 in revenue, down 100.0% from fiscal 2024, the first decline in the 14 years shown. Neurogene reported a net loss of $90.4 million, compared with a loss of $75.1 million a year earlier. Diluted earnings per share came in at -$4.24.

Neurogene annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$925.00K$0——
Growth-100.00%————
Net income$-90.35M$-75.14M$-36.32M$-55.19M$-60.69M
EPS (diluted)$-4.24$-4.28—$-1.04$-1.10

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$77.63+250.47%

  • Strong buy 1
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $46.00High $166.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.05 vs $-1.49
Surprise
+29.53%

NGNE news

All NGNE news

Neurogene peers

Health Care sector
NGNE peer companies
CompanyPrice% ChgMarket capCompare
GYREGyre Therapeutics Inc.4.21-6.86%$460.79Mvs NGNE
BLSMBlossomHill Therapeutics Inc.14.51+0.69%$461.20Mvs NGNE
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs NGNE
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs NGNE
RZLTRezolute Inc.3.92-6.67%$465.58Mvs NGNE
MNPRMonopar Therapeutics Inc.69.00-1.84%$467.60Mvs NGNE
EVOEvotec SE ADR1.32-8.97%$469.11Mvs NGNE
KMDAKamada Ltd.7.74-1.15%$446.85Mvs NGNE

Indexes, lists and sector

Neurogene stock FAQ

What is Neurogene's stock price today?

NGNE last traded at $22.15 as of Nov 20, 4:00 PM EST, down 3.40% on the day. Prices are delayed at least 15 minutes.

Does Neurogene pay a dividend?

No. Neurogene does not currently pay a regular cash dividend.

Who is Neurogene's CEO?

Dr. Rachel L. McMinn Ph.D. is the chief executive officer of Neurogene Inc., which has about 131 employees.

Has NGNE ever split its stock?

Yes. The most recent NGNE stock split was a 1-for-4 split on Dec 19, 2023, one of 2 splits on record.

What is the NGNE 52-week high?

The 52-week high for NGNE is $43.66 and the 52-week low is $15.93. The stock is currently 49.3% below its high.

Compare NGNE